Authors present a case of mucolipidosis III diagnosed in a boy suffering from articular retractions, platyspondylia and a normal mucolysacchariduria. Biochemical characteristics of the lisosomial enzyme, reduced in fibroblasts in culture and increased in biological fluids allow such diagnose. Primary enzyme lack being not yet explained, authors comment upon the hypothesis trying to explain biochemical findings.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Metachromatic Leukodystrophy in Morocco: Identification of Causative Variants by Next-Generation Sequencing (NGS).
Genes (Basel)
November 2024
Servicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS, 28034 Madrid, Spain.
(1) Background: Most rare disease patients endure long delays in obtaining a correct diagnosis, the so-called "diagnostic odyssey", due to a combination of the rarity of their disorder and the lack of awareness of rare diseases among both primary care professionals and specialists. Next-generation sequencing (NGS) techniques that target genes underlying diverse phenotypic traits or groups of diseases are helping reduce these delays; (2) Methods: We used a combination of biochemical (thin-layer chromatography and high-performance liquid chromatography-tandem mass spectrometry), NGS (resequencing gene panels) and splicing assays to achieve a complete diagnosis of three patients with suspected metachromatic leukodystrophy, a neurologic lysosomal disorder; (3) Results: Affected individuals in each family were homozygotes for harmful variants in the gene, one of them novel (c.854+1dup, in family 1) and the other already described (c.
View Article and Find Full Text PDFClinical and molecular characteristics of 20 Chinese probands with Mucolipidosis type II and III alpha/beta.
BMC Pediatr
December 2024
Department of Genetics and Endocrinology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 9 Jinsui Road, Guangzhou, 510623, China.
Background: Mucolipidosis (ML) II and III alpha/beta are lysosomal disorders caused by mutations in the GNPTAB gene which encodes the alpha and beta subunits of the heterohexameric enzyme, N-acetylglucosamine-1-phosphotransferase.
Method: To explore the clinical and molecular characteristics of the 20 ML II and III alpha/beta patients, clinical data was collected and GNPTAB gene was analyzed by nest PCR and direct Sanger-sequencing. The activity of several lysosomal enzymes was measured in the plasma.
Two cases of type I sialidosis and a literature review.
Orphanet J Rare Dis
November 2024
Department of Endocrinology, Beijing Children's Hospital, Capital Medical University, National Centre for Children's Health, Genetics, Metabolism, Beijing, 100045, China.
Article Synopsis
- The study compares clinical and genetic features of two Chinese children with type I sialidosis to previously reported cases, aiming to gather more insights into the disorder.
- The first patient, an 11-year-old girl, presented with short stature and vision problems linked to genetic mutations in the NEU1 gene, while the second patient, a 10-year-old boy, showed rapid weight gain and distinct visual impairments.
- Upon analyzing a total of 71 cases from the literature, common symptoms identified include muscle spasms and ataxia, highlighting the diverse manifestations of this genetic condition.
Progressive myoclonic ataxia as an initial symptom of typical type I sialidosis with NEU1 mutation.
Ann Clin Transl Neurol
November 2024
Department of Neurology and Institute of Neurology of First Affiliated Hospital, Institute of Neuroscience, and Fujian Key Laboratory of Molecular Neurology, Fujian Medical University, Fuzhou, 350005, China.
Article Synopsis
- * Researchers examined 231 patients and found that 31 had ST-1, with 80.6% of them carrying the c.544A>G mutation; they identified other NEU1 variants, including two novel ones.
- * The study concluded that ST-1 should be considered in Southeastern Chinese patients exhibiting PMA or ataxia symptoms, suggesting that genetic testing for the NEU1 c.544A>G mutation could be a key diagnostic
Multi-omic analysis of a mucolipidosis II neuronal cell model uncovers involvement of pathways related to neurodegeneration and drug metabolism.
Mol Genet Metab
November 2024
Greenwood Genetic Center, Greenwood, SC 29646, United States of America. Electronic address:
Defining the molecular consequences of lysosomal dysfunction in neuronal cell types remains an area of investigation that is needed to understand many underappreciated phenotypes associated with lysosomal disorders. Here we characterize GNPTAB-knockout DAOY medulloblastoma cells using different genetic and proteomic approaches, with a focus on how altered gene expression and cell surface abundance of glycoproteins may explain emerging neurological issues in individuals with GNPTAB-related disorders, including mucolipidosis II (ML II) and mucolipidosis IIIα/β (ML IIIα/β). The two knockout clones characterized demonstrated all the biochemical hallmarks of this disease, including loss of intracellular glycosidase activity due to impaired mannose 6-phosphate-dependent lysosomal sorting, lysosomal cholesterol accumulation, and increased markers of autophagic dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!